AMENDMENT

This listing of claims will replace all prior versions, and listings, of claims in the application. The listing of claims is as follows:

1. – 22. (Canceled)

Please add new claims 23-39 as follows:

23. (New). A compound of the following formula I, or a pharmaceutically acceptable salt thereof,:



(I)

wherein:

R^1 and R^2 are each independently selected from the group consisting of H, F, Cl, Br, I, NO_2, CF_3, CN, OCF_3, OH, C_1-C_4alkoxy-, C_1-C_4alkylcarbonyl-, C_1-C_6 alkyl, hydroxy C_1-C_4 alkyl-, C_3-C_6 alkenyl, C_3-C_6 alkynyl, C_3-C_{10} cycloalkyl(C_0-C_4alkyl)-, $H_2N(C_0$-$C_4)$alkyl-, $R^6HN(C_0$-$C_4)$alkyl-, $R^6R^7N(C_0$-$C_4)$alkyl-, $R^7S(C_0$-$C_4)$alkyl-, $R^7S(O)$ $(C_0$-$C_4)$alkyl-, $R^7SO_2(C_0$-$C_4)$alkyl-, $R^6NSO_2(C_0$-$C_4)$alkyl-, HSO_3, $HO_2C(C_0$-$C_4)$alkyl-, $R^6O_2C(C_0$-$C_4)$alkyl-, and $R^6R^7NCO(C_0$-$C_4)$alkyl-,

or R^1 and R^2, when on adjacent carbon atoms, and when taken together are methylenedioxy or ethylenedioxy;

R^5 is independently selected from H, F, Cl, Br, I, NO_2, CN, CF_3, OCF_3, OH, C_1-C_4alkoxy-, hydroxyC_1-C_4 alkyl-, C_1-C_4 alkylcarbonyl-, CO_2H, CO_2R^6, $CONR^6R^7$, NHR^6, and NR^6R^7;

R^6 is selected from H, C_1-C_8 alkyl, C_3-C_6 alkenyl, C_3-C_6 alkynyl, C_3-C_{10} cycloalkyl(C_0-C_4 alkyl)-, aryl(C_0-C_4 alkyl)-, and heterocyclic (C_0-C_4 alkyl)-,

wherein said aryl or heterocyclic groups are substituted with 0-2 substituents independently selected from C_1-C_4 alkyl, C_1-C_4 alkoxy, hydroxy C_0-C_4 alkyl, oxo, F, Cl, Br, CF_3, NO_2, CN, OCF_3, NH_2, NHR^7, NR^7R^8, SR^7, $S(O)R^7$, SO_2R^7, $SO_2NR^7R^8$, CO_2H, CO_2R^7, and $CONR^7R^8$;

R^7 and R^8 are each independently selected from H, C_1-C_8 alkyl, C_3-C_6 alkenyl, C_3-C_6 alkynyl, C_3-C_{10} cycloalkyl(C_0-C_4 alkyl)-, C_1-C_6 alkylcarbonyl, C_3-C_7 cycloalkyl(C_0-C_5 alkyl)carbonyl, C_1-C_6 alkoxycarbonyl, C_3-C_7 cycloalkyl(C_0-C_5 alkoxy)carbonyl, aryl(C_1-C_5 alkoxy)carbonyl, arylsulfonyl, aryl(C_0-C_4 alkyl)-, heterocyclic(C_1-C_5 alkoxy)carbonyl, heterocyclic sulfonyl and heterocyclic (C_0-C_4 alkyl)-, wherein said aryl or heterocyclic groups are substituted with 0-2 substituents independently selected from the group consisting of C_1-C_4 alkyl, C_1-C_4 alkoxy, F, Cl, Br, CF_3, CN, and NO_2;

or R^6 and R^7, or R^6 and R^8, or R^7 and R^8, when both substituents are on the same nitrogen atom, do or do not form, with the nitrogen atom to which they are attached, a heterocycle selected from 1-aziridinyl, 1-azetidinyl, 1-piperidinyl, 1-morpholinyl, 1-pyrrolidinyl, thiamorpholinyl, thiazolidinyl, and 1-piperazinyl, said heterocycle is unsubstituted or substituted with 0-3 groups selected from oxo, C_1-C_6 alkyl, C_3-C_7 cycloalkyl(C_0-C_4 alkyl)-, C_1-C_6 alkylcarbonyl, C_3-C_7 cycloalkyl(C_0-C_5 alkyl)carbonyl, C_1-C_6 alkoxycarbonyl, C_3-C_7 cycloalkyl(C_0-C_5 alkoxy)carbonyl, aryl(C_0-C_5 alkyl), heterocyclic(C_0-C_5 alkyl), aryl(C_1-C_5 alkoxy)carbonyl, heterocyclic(C_1-C_5 alkoxy)carbonyl, C_1-C_6 alkylsulfonyl, arylsulfonyl, and heterocyclicsulfonyl,

wherein said aryl or heterocyclic groups are substituted with 0-2 substituents independently selected from C_1-C_4 alkyl, C_1-C_4 alkoxy, F, Cl, Br, CF_3, CN, and NO_2;

K is selected from -C(=O)- and -CHR^9-;

L is selected from -C(=O), -CHR^9-, -$CR^{10}R^{11}$-, -$CR^{10}R^{11}$-(C=O), -$HR^{15}C$-CHR^{16}-, and -$R^{15}C$=CR^{16};

R^9 is selected from H, C_1-C_8 alkyl, C_3-C_6 alkenyl, C_3-C_{10} cycloalkyl(C_0-C_4 alkyl)-, aryl(C_0-C_4 alkyl)-, and heterocyclic(C_0-C_4 alkyl)-,

wherein said aryl or heterocyclic groups are substituted with 0-2 substituents independently selected from C_1-C_4 alkyl, C_1-C_4 alkoxy, F, Cl, Br, CF_3, and NO_2;

R^{10} is selected from H, F, Cl, Br, C_1-C_6 alkoxy, C_1-C_8 alkyl, C_3-C_6 alkenyl, C_3-C_{10} cycloalkyl(C_0-C_4 alkyl)-, aryl(C_0-C_4 alkyl)-, and heterocyclic(C_0-C_4 alkyl)-, wherein said aryl or heterocyclic groups are substituted with 0-2 substituents independently selected from C_1-C_4 alkyl, C_1-C_4 alkoxy, F, Cl, Br, CF_3, CN, and NO_2;

R^{11} is selected from H, F, Cl, Br, OMe, C_1-C_8 alkyl, C_3-C_6 alkenyl, C_3-C_{10} cycloalkyl(C_0-C_4 alkyl)-, aryl(C_0-C_4 alkyl)-, and heterocyclic(C_0-C_4 alkyl)-, wherein said aryl or heterocyclic groups are substituted with 0-2 substituents independently selected from C_1-C_4 alkyl, C_1-C_4 alkoxy, F, Cl, Br, CF_3, CN, and NO_2;

or R^{10} and R^{11}, when on the same carbon atom, do or do not form, with the carbon atoms to which they are attached, a 3-7 membered carbocyclic or 3-7 membered heterocyclic non-aromatic ring system, said carbocyclic or heterocyclic ring is unsubstituted or substituted with 0-2 substituents independently selected from C_1-C_4 alkyl, C_1-C_4 alkoxy, hydroxy C_0-C_4 alkyl, oxo, F, Cl, Br, CF_3, and NO_2;

R^{12} is selected from H, C_3-C_6 alkenyl, C_3-C_{10} cycloalkyl(C_0-C_4 alkyl)-, monocyclic or bicyclic 5-10 membered heterocyclic(C_0-C_4 alkyl)-, and $-CZ^1Z^2Z^3$, provided $-CZ^1Z^2Z^3$ is not C_1-C_8 alkyl,

wherein said aryl or heterocyclic groups are substituted with 0-3 substituents independently selected from R^{14};

Z^1 is selected from C_1-C_8 alkyl, C_2-C_6 alkenyl, C_2-C_6 alkynyl, C_1-C_6 hydroxyalkyl, C_1-C_4 alkoxy C_1-C_4 alkyl, aryl(C_0-C_4 alkyl)-, and 4-10 membered heterocyclic (C_0-C_4 alkyl)-,

wherein said aryl or heterocyclic groups are substituted with 0-3 substituents independently selected from R^{14};

Z^2 is selected from C_1-C_8 alkyl, C_2-C_6 alkenyl, C_2-C_6 alkynyl, C_1-C_6 hydroxyalkyl, C_1-C_4 alkoxy C_1-C_4 alkyl, C_1-C_6 $NR^{17}R^{18}$, aryl(C_0-C_4 alkyl)-, and 4-10 membered heterocyclic (C_0-C_4 alkyl)-,

wherein said aryl or heterocyclic groups are substituted with 0-3 substituents independently selected from R^{14};

Z^3 is selected from C_1-C_8 alkyl, R^{14}(C_2-C_4 alkyl)-, C_2-C_6 alkenyl, C_2-C_6 alkynyl, C_1-C_6 hydroxyalkyl, C_1-C_4 alkoxy C_1-C_4 alkyl, aryl(C_0-C_4 alkyl)-, 4-10 membered heterocyclic (C_0-C_4 alkyl)-, $R^{17}O=C(C_0$-C_4 alkyl)-, $R^{17}OO=C(C_0$-C_4 alkyl)-, and $R^{17}R^{18}$ $NO=C(C_0$-C_4 alkyl)-,

wherein said aryl or heterocyclic groups are substituted with 0-3 substituents independently selected from R^{14};

or Z^1 and Z^2, when on the same carbon atom, may form, with the carbon atoms to which they are attached, a 3-7 membered carbocyclic or 3-7 membered heterocyclic non-aromatic ring

system, said carbocyclic or heterocyclic ring may be substituted with 0-2 substituents independently selected from R^{14}.

R^{13} is selected from H, C_1-C_8 alkyl, C_3-C_6 alkenyl, C_3-C_{10} cycloalkyl(C_0-C_4 alkyl)-, C_1-C_6 alkylcarbonyl, C_1-C_6 alkylsulfonyl, C_3-C_7 cycloalkyl(C_0-C_5 alkyl)carbonyl, C_1-C_6 alkoxycarbonyl, C_3-C_7 cycloalkyl(C_0-C_5 alkoxy)carbonyl, aryl(C_0-C_4 alkyl)-, aryl(C_1-C_5 alkoxy)carbonyl , arylsulfonyl, heterocyclic(C_0-C_4 alkyl), heterocyclic(C_1-C_5 alkoxy)carbonyl, and heterocyclicsulfonyl,

wherein said aryl or heterocyclic groups are substituted with 0-2 substituents independently selected from C_1-C_4 alkyl, C_1-C_4 alkoxy, F, Cl, Br, CF_3, CN, and NO_2;

R^{14} is selected from H, C_1-C_{10} alkyl, NO_2, CF_3, CN, F, Cl, Br, C_1-C_{10} alkylcarbonyl, haloalkyl, haloalkoxy, OH, NR^6R^7(C_0-C_4 alkyl)-, R^6 C(=O)O(C_0-C_4 alkyl)-, $R^6OC(=O)O$ (C_0-C_4 alkyl)-, R^6O (C_0-C_4 alkyl), R^6R^7 NC(=O) O(C_0-C_4 alkyl)-, R^6R^7 NC(=O) (C_0-C_4 alkyl)-, $R^6O(CR^{10}R^{11})_{2\text{-}6}R^6NC(=O)$ (C_0-C_4 alkyl)-, $R^6R^7N(CR^{10}R^{11})_{2\text{-}6}R^6NC(=O)$ (C_0-C_4 alkyl)-, $R^6O_2C(CH_2)_{1\text{-}4}O$($C_0$-$C_4$ alkyl)-, R^6OOC(C_1-C_4 alkoxy),- R^6OOC(C_0-C_4 alkyl)-, $R^6C(=O)$(C_0-C_4 alkyl)-, $R^6C(=O)NR^7$(C_0-C_4 alkyl)-, $R^6OC(=O)NR^7$(C_0-C_4 alkyl)-, $R^6OC(=NCN)NR^7$(C_0-C_4 alkyl)-, $R^6R^7NC(=O)NR^8$(C_0-C_4 alkyl)-, $R^6OC(=NC)$ NR^7(C_0-C_4 alkyl)-, $R^6(CR^{10}R^{11})_{1\text{-}4}$ $NR^7C=O$-, R^6O $(CR^{10}R^{11})_{1\text{-}4}O=CR^7N$-, $NR^6R^7(CR^{10}R^{11})_{1\text{-}4}$ C=O R^7N-, $R^6O(CR^{10}R^{11})_{2\text{-}4}R^7N$-, $R^6O_2C(CR^{10}R^{11})_{1\text{-}4}R^7N$, R^6R^7N $(CR^{10}R^{11})_{2\text{-}4}R^7N$-, $R^6R^7NC(=NCN)NR^7$(C_0-C_4 alkyl)-, $R^6R^7NC(=C(H)(NO_2))NR^7$($C_0$-$C_4$ alkyl)-, R^7R^8N $C(=NR^7)$ NR^7(C_0-C_4 alkyl)-, R^6R^7N SO_2NR^8(C_0-C_4 alkyl)-, $R^6SO_2NR^7$(C_0-C_4 alkyl)-, R^6R^7N(C_1-C_4) CO-, R^6R^7N(C_2-C_6 alkyl)O-, $R^6CO(CR^{10}R^{11})_{0\text{-}2}$ $R^7N(O_2)S$(C_0-C_4 alkyl), $R^6(O_2)S$ R^7 NC(=O) (C_0-C_4 alkyl)-, R^6S(C_0-C_4 alkyl)-, $R^6S(=O)$ (C_0-C_4 alkyl)-, R^6SO_2(C_0-C_4 alkyl)-, $SO_2NR^6R^7$, $SiMe_3$, R^6R^7N(C_2-C_4 alkyl)-, R^6R^7N(C_2-C_4 alkoxy)-, HSO_3, HONH-, R^6ONH-, $R^8R^7NNR^6$-, $HO(COR^6)N$-, $HO(R^6O_2C)N$, C_2-C_6 alkenyl, C_3-C_{10} cycloalkyl, C_3-C_{10} cycloalkylmethyl, aryl(C_0-C_4alkyl)-, heteroaryl(C_0-C_4alkyl)-, aryl(C_0-C_4alkyl)O-, and heteroaryl(C_0-C_4alkyl)O-,

wherein said aryl groups are substituted with 0-2 substituents independently selected from C_1-C_4 alkyl, C_1-C_4 alkoxy, F, Cl, Br, CF_3, and NO_2;

R^{15} is selected from H, halo, cyano, C_1-C_8 alkyl, C_3-C_6 alkenyl, and C_3-C_{10} cycloalkyl(C_0-C_4 alkyl)-, aryl(C_0-C_4 alkyl)-, and heterocyclic(C_0-C_4 alkyl)-,

wherein said aryl or heterocyclic groups are substituted with 0-2 substituents independently selected from R^{14}; and

R^{16} is selected from H, halo, cyano, C_1-C_8 alkyl, C_3-C_6 alkenyl, C_3-C_{10} cycloalkyl(C_0-C_4 alkyl)-, aryl(C_0-C_4 alkyl)-, and heterocyclic(C_0-C_4 alkyl)-,

wherein said aryl or heterocyclic groups are substituted with 0-2 substituents independently selected from R^{14};

or when R^{15} and R^{16} are on adjacent carbon atoms, or when R^{15} and R^{16} are oriented on the same side of the double bond, as depicted in the following structure (III)



(III),

R^{15} and R^{16} do or do not form, with the carbon atoms to which they are attached, a 3-7 membered carbocyclic aromatic or nonaromatic ring system, or a 3-7 membered heterocyclic aromatic or nonaromatic ring system, said carbocyclic or heterocyclic ring is unsubstituted or substituted with 0-2 substituents independently selected from C_1-C_4 alkyl, C_1-C_4 alkoxy, F, Cl, Br, CF_3,and NO_2;

R^{17} is selected from H, C_1-C_8 alkyl, C_3-C_6 alkenyl, C_3-C_{10} cycloalkyl(C_0-C_4 alkyl)-, C_1-C_6 alkylcarbonyl, C_1-C_6 alkylsulfonyl, C_3-C_7 cycloalkyl(C_0-C_5 alkyl)carbonyl, C_1-C_6 alkoxycarbonyl, C_3-C_7 cycloalkyl(C_0-C_5 alkoxy)carbonyl, hydroxy(C_2-C_4)alkyl-, C_1-C_3 alkoxy(C_2-C_4)alkyl-, (C_0-C_4 alkyl) (C_0-C_4 alkyl) amino(C_2-C_4)alkyl-, aryl(C_0-C_4 alkyl)-, aryl(C_1-C_5 alkoxy)carbonyl , arylsulfonyl, heterocyclic(C_0-C_4 alkyl), heterocyclic(C_1-C_5 alkoxy)carbonyl, and heterocyclicsulfonyl,

wherein said aryl or heterocyclic groups are substituted with 0-2 substituents independently selected from C_1-C_4 alkyl, C_1-C_4 alkoxy, C_1-C_4 alkoxy C_1-C_4 alkyl, oxo, F, Cl, Br, CF_3, CN, and NO_2; and

R^{18} is selected from H, C_1-C_8 alkyl, C_3-C_6 alkenyl, C_3-C_{10} cycloalkyl(C_0-C_4 alkyl)-, aryl(C_0-C_4 alkyl)-, and heterocyclic(C_0-C_4 alkyl),

wherein said aryl or heterocyclic groups are substituted with 0-2 substituents independently selected from C_1-C_4 alkyl, C_1-C_4 alkoxy, F, Cl, Br, CF_3, CN, and NO_2;

or R^{17} and R^{18}, when both are on the same nitrogen atom, may form, with the nitrogen atom to which they are attached, a heterocycle selected from 1-aziridinyl, 1-azetidinyl, 1-piperidinyl, 1-morpholinyl, 1-pyrrolidinyl, thiamorpholinyl, thiazolidinyl, and 1-piperazinyl,

said heterocycle may be substituted with 0-3 groups selected from oxo, C_1-C_6 alkyl, C_3-C_7 cycloalkyl(C_0-C_4 alkyl)-, C_1-C_6 alkylcarbonyl, (C_1-C_6 alkylcarbonyl)(C_0-C_4alkyl)amino-, C_3-C_7 cycloalkyl(C_0-C_5 alkyl)carbonyl, C_1-C_6 alkoxycarbonyl, C_3-C_7 cycloalkyl(C_0-C_5 alkoxy)carbonyl, aryl(C_0-C_5 alkyl), heterocyclic(C_0-C_5 alkyl), aryl(C_1-C_5 alkoxy)carbonyl, heterocyclic(C_1-C_5 alkoxy)carbonyl, C_1-C_6 alkylsulfonyl arylsulfonyl and heterocyclicsulfonyl,

wherein said aryl or heterocyclic groups are substituted with 0-2 substituents independently selected from CH_3-, alkoxy, F, Cl, Br, CF_3, CN, and NO_2.

24. (New) A compound or pharmaceutically acceptable salt thereof of Claim 23 having the formula,



wherein

R^1 and R^2 are each independently selected from the group consisting of H, F, Cl, Br, I, NO_2, CF_3, CN, OCF_3, OH, C_1-C_4alkoxy-, and C_1-C_4alkyl-;

R^5 is selected from the group consisting of H, F, Cl, Br, I, NO_2, CN, CF_3, OCF_3, OH, C_1-C_4alkoxy, and CO_2H; and

R^7 is selected from hydrogen and C_1-C_8 alkyl.

25. (New) The compound or a pharmaceutically acceptable salt thereof of Claim 24 wherein

R^5 is H;

R^1 is selected from the group consisting of OCF_3 and C_1-C_4alkoxy;

R^2 is H; and

R^{13} is hydrogen.

26. (New). The compound or a pharmaceutically acceptable salt thereof of Claim 25 wherein:

K is C(=O); and

L is C(=O).

27. (New) The compound or a pharmaceutically acceptable salt thereof of Claim 26 having the formula,



wherein R^{12} is $-CZ^1Z^2Z^3$.

28. (New) The compound or a pharmaceutically acceptable salt thereof of Claim 27 wherein:

R^7 is hydrogen; and

R^1 is methoxy.

29. (New) The compound or a pharmaceutically acceptable salt thereof of Claim 28 wherein Z^1 and Z^2 are independently selected from C_1-C_8 alkyl.

30.(New) The compound or a pharmaceutically acceptable salt thereof of Claim 25 wherein:

K is C(=O) and

L is CHR^9.

31. (New). A compound or a pharmaceutically acceptable salt thereof of Claim 25 wherein:

K is $CHR^9$and

L is C(=O).

32. (New) A compound or a pharmaceutically acceptable salt thereof of Claim 25 wherein:

K is C(=O) and

L is $-CR^{10}R^{11}$-(C=O).

33. (New) A compound or pharmaceutically acceptable salt thereof, wherein said compound is selected from:

N-[3-Methoxy-4-(5-oxazolyl)phenyl]-N'-(phenylmethyl)ethanediamide;

N-[1,1-Bis(hydroxymethyl)propyl]-N'-[3-methoxy-4-(5-oxazolyl)phenyl]ethanediamide;

N-(2-Hydroxy-1,1-dimethylethyl)-N'-[3-methoxy-4-(5-oxazolyl)phenyl]ethanediamide;

N-[[[3-Methoxy-4-(5-oxazolyl)phenyl]amino]oxoacetyl]-2-methylalanine 1,1-dimethylethyl ester;

N-(2-Hydroxy-1,1-dimethylpentyl)-N'-[3-methoxy-4-(5-oxazolyl)phenyl]ethanediamide;

N-[2-[(2-Hydroxy-1,1-dimethylethyl)amino]-1,1-dimethylethyl]-N'-[3-methoxy-4-(5-oxazolyl)phenyl]ethanediamide;

N-[2-(Dimethylamino)-1,1-dimethylethyl]-N'-[3-methoxy-4-(5-oxazolyl)phenyl]ethanediamide;

N-(1,1-Diethyl-2-propynyl)-N'-[3-methoxy-4-(5-oxazolyl)phenyl]ethanediamide;

N-[1-(Hydroxymethyl)cyclopentyl]-N'-[3-methoxy-4-(5-oxazolyl)phenyl]ethanediamide;

N-[2-(4-Fluorophenyl)-1,1-dimethylethyl]-N'-[3-methoxy-4-(5-oxazolyl)phenyl]ethanediamide;

N-[[[3-Methoxy-4-(5-oxazolyl)phenyl]amino]oxoacetyl]-α -methyltyrosine methyl ester;

N-[[[3-Methoxy-4-(5-oxazolyl)phenyl]amino]oxoacetyl]-a-methyltryptophan methyl ester;

N-[1,1-Bis(hydroxymethyl)ethyl]-N'-[3-methoxy-4-(5-oxazolyl)phenyl]-N-methylethanediamide;

N-(1,1-Dimethyl-3-oxobutyl)-N'-[3-methoxy-4-(5-oxazolyl)phenyl]ethanediamide;

N-[3-Methoxy-4-(5-oxazolyl)phenyl]-N'-(1-methyl-1-phenylethyl)ethanediamide;

N-(2-Hydroxy-1,2-dimethyl-1-phenylpropyl)-N'-[3-methoxy-4-(5-oxazolyl)phenyl]ethanediamide;

N-[[[3-Methoxy-4-(5-oxazolyl)phenyl]amino]oxoacetyl]-2-methylalanine methyl ester;

-[[[[3-Methoxy-4-(5-oxazolyl)phenyl]amino]oxoacetyl]amino]cyclopropanecarboxylic acid methyl ester;

N-(1-Ethynylcyclohexyl)-N'-[3-methoxy-4-(5-oxazolyl)phenyl]ethanediamide;

(R)-N-[1-(Hydroxymethyl)-1-methylpropyl]-N'-[3-methoxy-4-(5-oxazolyl)phenyl]-N-methylethanediamide;

N-[[[3-Methoxy-4-(5-oxazolyl)phenyl]amino]oxoacetyl]-2-methylalanine;

N-[1,1-Dimethyl-2-oxo-2-(1-piperidinyl)ethyl]-N'-[3-methoxy-4-(5-oxazolyl)phenyl]ethanediamide;

N-[1,1-Dimethyl-2-(4-methyl-1-piperazinyl)-2-oxoethyl]-N'-[3-methoxy-4-(5-oxazolyl)phenyl]ethanediamide;

N-[1,1-Dimethyl-2-(4-morpholinyl)-2-oxoethyl]-N'-[3-methoxy-4-(5-oxazolyl)phenyl]ethanediamide;

4-[2-[[[[3-Methoxy-4-(5-oxazolyl)phenyl]amino]oxoacetyl]amino]-2-methyl-1-oxopropyl]-1-piperazinecarboxylic acid ethyl ester;

N-[2-[3-(Acetylmethylamino)-1-pyrrolidinyl]-1,1-dimethyl-2-oxoethyl]-N'-[3-methoxy-4-(5-oxazolyl)phenyl]ethanediamide;

N-[1,1-Dimethyl-2-[methyl[2-(methylamino)ethyl]amino]-2-oxoethyl]-N'-[3-methoxy-4-(5-oxazolyl)phenyl]ethanediamide;

N-[1,1-Dimethyl-2-oxo-2-(propylamino)ethyl]-N'-[3-methoxy-4-(5-oxazolyl)phenyl]ethanediamide;

N-[1,1-Dimethyl-2-[[2-(methylamino)ethyl]amino]-2-oxoethyl]-N'-[3-methoxy-4-(5-oxazolyl)phenyl]ethanediamide;

N-[1,1-Dimethyl-2-[[2-(4-morpholinyl)ethyl]amino]-2-oxoethyl]-N'-[3-methoxy-4-(5-oxazolyl)phenyl]ethanediamide;

N-[1,1-Dimethyl-2-oxo-2-[[3-(2-oxo-1-pyrrolidinyl)propyl]amino]ethyl]-N'-[3-methoxy-4-(5-oxazolyl)phenyl]ethanediamide;

N-[2-[[2-(1H-Imidazol-4-yl)ethyl]amino]-1,1-dimethyl-2-oxoethyl]-N'-[3-methoxy-4-(5-oxazolyl)phenyl]ethanediamide;

N-[2-[[2-(Acetylamino)ethyl]amino]-1,1-dimethyl-2-oxoethyl]-N'-[3-methoxy-4-(5-oxazolyl)phenyl]ethanediamide;

N-[2-[[2-(1H-Imidazol-1-yl)ethyl]amino]-1,1-dimethyl-2-oxoethyl]-N'-[3-methoxy-4-(5-oxazolyl)phenyl]ethanediamide;

N-[1,1-Dimethyl-2-oxo-2-[[2-(4-pyridinyl)ethyl]amino]ethyl]-N'-[3-methoxy-4-(5-oxazolyl)phenyl]ethanediamide;

N-[1,1-Dimethyl-2-oxo-2-[[(tetrahydro-2-furanyl)methyl]amino]ethyl]-N'-[3-methoxy-4-(5-oxazolyl)phenyl]ethanediamide;

N-[2-[(2-Methoxyethyl)amino]-1,1-dimethyl-2-oxoethyl]-N'-[3-methoxy-4-(5-oxazolyl)phenyl]ethanediamide;

N-[2-(Dimethylamino)-1,1-dimethyl-2-oxoethyl]-N'-[3-methoxy-4-(5-oxazolyl)phenyl]ethanediamide;

N-[2-[4-(2-Methoxyethyl)-1-piperazinyl]-1,1-dimethyl-2-oxoethyl]-N'-[3-methoxy-4-(5-oxazolyl)phenyl]ethanediamide; and

N-[1,1-Dimethyl-2-oxo-2-(2-pyridinylamino)ethyl]-N'-[3-methoxy-4-(5-oxazolyl)phenyl]ethanediamide.

34. (Amended). A pharmaceutical composition comprising a pharmaceutically acceptable carrier, adjuvant or vehicle and at least one compound of claim 23, or a pharmaceutically acceptable salt thereof, in an amount effective therefor.

35. (New). A method for the treatment of an IMPDH-associated disorder, comprising the step of administering to a subject in need thereof an amount effective therefor of at least one compound of claim 23 or a pharmaceutically acceptable salt thereof.

36. (New). The method of claim 35, wherein said IMPDH-associated disorder is selected from an autoimmune disorder, an inflammatory disorder, a cancer or tumor disorder, a DNA or RNA viral replication disease, and allograft rejection.

37.(New). The method of claim 36, wherein said IMPDH-associated disorder is selected from transplant rejection, rheumatoid arthritis, inflammatory bowel disease, hepatitis B, hepatitis C, herpes simplex type I, and herpes simplex type II.

38. (New). The method of claim 37, wherein said compound of claim 23, or a pharmaceutically acceptable salt thereof, is administered with one or more of: an immunosuppressant, an anti-cancer agent, an anti-viral agent, an anti-inflammatory agent, an anti-fungal agent, an antibiotic, an anti-

vascular hyperproliferation compound, or an IMPDH inhibitor other than a compound of claim 23 or a pharmaceutically acceptable salt thereof.

39. (New). The method of claim 38 wherein said compound of claim 23 or a pharmaceutically acceptable salt thereof, is administered with one or more of: another IMPDH inhibitor; a cyclosporin; CTLA4-Ig; an antibody selected from anti-ICAM-3, anti-IL-2 receptor (Anti-Tac), anti-CD45RB, anti-CD2, anti-CD3 (OKT-3), anti-CD4, anti-CD80, anti-CD86, and monoclonal antibody OKT3; an agent blocking the interaction between CD40 and CD154; a fusion protein constructed from CD40 and/or CD154/gp39; an inhibitor of NF-kappa B function; a non-steroidal antiinflammatory drug (NSAID); a gold compound; an antiviral agent; an antiproliferative ; a cytotoxic drug; an TNF-α inhibitor; an anti-TNF antibody; a soluble TNF receptor; and rapamycin (sirolimus or Rapamune); or derivatives thereof.